Insights

HLA Platform Focus IM Therapeutics is building an HLA-directed platform aimed at autoimmune diseases with early efficacy in type 1 diabetes, presenting a clear opportunity to engage partners seeking precision immunotherapies and niche autoimmune indications.

Clinical Stage Assets As a clinical-stage company with a Phase 1b MAD trial launched in 2020, IM Therapeutics may attract collaboration or licensing discussions, particularly with larger biotech firms seeking early-stage assets in autoimmune targets.

Leadership Additions Recent hires in immunology leadership and board members signal a bolstering of scientific credibility and governance, creating openings for strategic alliances, co-development, or advisory partnerships with organizations prioritizing neuromuscular or autoimmune pipelines.

Funding Momentum With a $10M Series A and a revenue profile under $1M, there is an opportunity to approach with strategic funding peers, grant opportunities, or venture co-investment to accelerate platform expansion and lead candidate development.

Partnership Fit The focus on targeted HLA therapies positions IM Therapeutics as a potential collaborator for big pharma or specialty biotech players seeking to augment their autoimmune portfolios with precision, antigen-specific approaches and personalized medicine capabilities.

Similar companies to IM Therapeutics

IM Therapeutics Tech Stack

IM Therapeutics uses 8 technology products and services including WordPress, Webpack, Google Workspace, and more. Explore IM Therapeutics's tech stack below.

  • Content Management System
  • Webpack
    Development
  • Twemoji
    Font Scripts
  • jQuery
    Javascript Libraries
  • Modernizr
    Javascript Libraries
  • PHP
    Programming Languages
  • GoDaddy
    Web Hosting

Media & News

IM Therapeutics's Email Address Formats

IM Therapeutics uses at least 1 email format:
IM Therapeutics Email FormatsExamplePercentage
FLast@imtherapeutics.comJDoe@imtherapeutics.com
100%

Frequently Asked Questions

What is IM Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
IM Therapeutics's official website is imtherapeutics.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does IM Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, IM Therapeutics's annual revenue is estimated to be <$1M.

What is IM Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
IM Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does IM Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, IM Therapeutics has approximately 4 employees across 1 continents, including North America. Key team members include Cmc And Regulatory Senior Manager: K. S. Explore IM Therapeutics's employee directory with LeadIQ.

What industry does IM Therapeutics belong to?

Minus sign iconPlus sign icon
IM Therapeutics operates in the Biotechnology Research industry.

What technology does IM Therapeutics use?

Minus sign iconPlus sign icon
IM Therapeutics's tech stack includes WordPress, Webpack, Google Workspace, Twemoji, jQuery, Modernizr, PHP and GoDaddy.

What is IM Therapeutics's email format?

Minus sign iconPlus sign icon
IM Therapeutics's email format typically follows the pattern of FLast@imtherapeutics.com. Find more IM Therapeutics email formats with LeadIQ.

How much funding has IM Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, IM Therapeutics has raised $10M in funding. The last funding round occurred on Oct 09, 2019 for $10M.

When was IM Therapeutics founded?

Minus sign iconPlus sign icon
IM Therapeutics was founded in 2015.
IM Therapeutics logo

IM Therapeutics

Biotechnology ResearchMassachusetts, United States2-10 Employees

IM Therapeutics is a biotechnology research company focused on developing therapies directed at human leukocyte antigens (HLAs) to treat autoimmune diseases. The firm is building an HLA-directed platform and has demonstrated early effectiveness in type 1 diabetes, with a pipeline aimed at targeted therapies across autoimmune conditions. Its customers are likely to be researchers and healthcare stakeholders seeking precision, first-in-class autoimmune treatments, addressing unmet needs in disease management. Based in Woburn, Massachusetts, the company operates in the biotechnology research sector and has pursued growth through a clinical-stage program and a leadership team with appointments in immunology and governance. A recent development includes advancing its clinical efforts with leadership hires and strategic milestones as part of its progression in precision medicine for autoimmune disease.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
2-10

Section iconFunding & Financials

  • $10M

    IM Therapeutics has raised a total of $10M of funding over 1 rounds. Their latest funding round was raised on Oct 09, 2019 in the amount of $10M as a Series A.

  • <$1M

    IM Therapeutics's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.